Alma B. Pederson, MD, PhD, DMSc, of Aarhus University Hospital in Demark led a historical cohort study of 90,000-plus patients treated with denosumab or alendronate.  The study revealed that the competing antiosteoporosis therapies result in a similar rate of patient bone fractures over 3 years. In addition to the Aarhus team investigators came from the UK and Spain.

Lead Research/Investigator

Alma B. Pederson, MD, PhD, DMSc

Source: MD Mag

Pin It on Pinterest